ATLANTA, GA – – (Globe Newswire – January 9, 2025) – – A shareholder class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA). The lawsuit alleges that the Company’s registration statement issued in connection with its IPO was false and/or misleading because Defendants failed to disclose safety concerns related to its lead product candidate, azelaprag.

If you bought shares of BioAge on or after September 26, 2024 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/bioage-labs/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 10, 2025.